Table 1.
Population characteristics of prospective cohort of atorvastatin- and rosuvastatin-treated patients
| Atorvastatin | Rosuvastatin | |
|---|---|---|
| Number of patients | 134 | 165 |
| Male | 83 (61.9%) | 115 (69.7%) |
| Age at enrolment (years) | 59.5 (24-86) | 59 (18-80) |
| Caucasian | 113 (83.7%) | 143 (86.7%) |
| Body mass index (kg/m2) | 29.0 (5.2) | 30.1 (6.8) |
| Number of concomitant medications | 4.9 (3.1) | 4.7 (3.1) |
| Statin dose (mg/kg) | 0.45 (0.31) | 0.22 (0.15) |
| 5 mg | -- | 24 (14.5%) |
| 10 mg | 22 (16.4%) | 52 (31.5%) |
| 20 mg | 30 (22.4%) | 47 (28.4%) |
| 40 mg | 58 (43.2%) | 38 (23.0%) |
| 80 mg | 23 (17.1%) | -- |
| Other | 1 (0.7%) | 4 (2.4%) |
| Hours from last dose | 12.9 (5.0) | 11.5 (5.3) |
| 4β-hydroxycholesterol (ng/mL) | 22.0 (14.1) | 18.7 (11.9) |
| Lathosterol (μg/mL) | 3.9 (2.1) | 3.4 (2.2) |
| Minor allelic frequency | ||
| ABCG2 c.421A | 25/268 (9.3%) | 36/330 (10.9%) |
| SLCO1B1 c.388G | 119/268 (44.4%) | 145/330 (43.9%) |
| SLCO1B1 c.521C | 30/268 (11.2%) | 61/330 (18.5%) |
Data are presented as number (%), mean (S.D.), or median (range).